The march toward malaria vaccines

Vaccine

Volumn 33, Issue , 2015, Pages D13-D23

  Hoffman, Stephen L ^a   Vekemans, Johan ^b   Richie, Thomas L ^a   Duffy, Patrick E ^c  

^a SANARIA INC   (United States)

^b GSK   (Belgium)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Malaria; Malaria elimination; Malaria prevention; Malaria vaccines; Plasmodium falciparum; Plasmodium falciparum vaccines; Vaccine

Indexed keywords

CELL ANTIBODY; CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; RTS,S VACCINE; SPOROZOITE VACCINE; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ADJUVANT THERAPY; AFRICA SOUTH OF THE SAHARA; CELLULAR IMMUNITY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; HUMAN; MALARIA; MORTALITY; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PRIORITY JOURNAL; REVIEW; ANIMAL; DISEASE ERADICATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; LIFE CYCLE STAGE; MALARIA, FALCIPARUM; MALARIA, VIVAX; PARASITOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); SPOROZOITE;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE ERADICATION; HUMANS; IMMUNITY, CELLULAR; LIFE CYCLE STAGES; MALARIA VACCINES; MALARIA, FALCIPARUM; MALARIA, VIVAX; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; RECOMBINANT PROTEINS; SPOROZOITES;

EID: 84951566716     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.091     Document Type: Review

References (110)

1. World Health Organization World malaria report 2014 2014, World Health Organization, Geneva.
2. Hoffman S.L., Miller L.H. Perspectives on malaria vaccine development. Malaria vaccine development: a multi-immune response approach 1996, 1-13. ASM Press, Washington, DC. S.L. Hoffman (Ed.).
3. Alonso P.L., Ballou R., Brown G., Chitnis C., Loucq C., Moorthy V., et al. A research agenda for malaria eradication: vaccines. PLoS Med 2011, 8:e1000398.
4. Coppi A., Natarajan R., Pradel G., Bennett B.L., James E.R., Roggero M.A., et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J Exp Med 2011, 208:341-356.
5. Kumar K.A., Sano G., Boscardin S., Nussenzweig R.S., Nussenzweig M.C., Zavala F., et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 2006, 444:937-940.
6. Egan J.E., Weber J.L., Ballou W.R., Hollingdale M.R., Majarian W.R., Gordon D.M., et al. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science 1987, 236:453-456.
7. Schofield L., Villaquiran J., Ferreira A., Schellekens H., Nussenzweig R.S., Nussenzweig V. Gamma-interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987, 330:664-666.
8. Ballou W.R., Hoffman S.L., Sherwood J.A., Hollingdale M.R., Neva F.A., Hockmeyer W.T., et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987, 1:1277-1281.
9. Herrington D.A., Clyde D.F., Losonsky G., Cortesia M., Murphy J.R., Davis J., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987, 328:257-259.
10. Gordon D.M., McGovern T.W., Krzych U., Cohen J.C., Schneider I., LaChance R., et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995, 171:1576-1585.
11. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997, 336:86-91.
12. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001, 183:640-647.
13. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346.
14. Garcon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
15. White M.T., Bejon P., Olotu A., Griffin J.T., Riley E.M., Kester K.E., et al. The relationship between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. PLOS ONE 2013, 8:e61395.
16. White M.T., Bejon P., Olotu A., Griffin J.T., Bojang K., Lusingu J., et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med 2014, 12:117.
17. Agnandji S.T., Asante K.P., Lyimo J., Vekemans J., Soulanoudjingar S.S., Owusu R., et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 2010, 202:1076-1087.
18. Asante K.P., Abdulla S., Agnandji S., Lyimo J., Vekemans J., Soulanoudjingar S., et al. Safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011, 11:741-749.
19. Leach A., Vekemans J., Lievens M., Ofori-Anyinam O., Cahill C., Owusu-Agyei S., et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J 2011, 10:224.
20. Moorthy V.S., Reed Z., Smith P.G. MALVAC 2008: measures of efficacy of malaria vaccines in phase 2b and phase 3 trials - scientific, regulatory and public health perspectives. Vaccine 2009, 27:624-628.
21. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875.
22. Agnandji S., Lell B., Fernandes J., Abossolo B., Methogo B., Kabwende A., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367:2284-2295.
23. RTSS Clinical Trials Partnership Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014, 11:e1001685.
24. Olotu A., Fegan G., Wambua J., Nyangweso G., Awuondo K.O., Leach A., et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med 2013, 368:1111-1120.
25. RTSS Clinical Trials Partnership Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015, 386:31-45.
26. Clyde D.F., Most H., McCarthy V.C., Vanderberg J.P. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 1973, 266:169-177.
27. Rieckmann K.H., Carson P.E., Beaudoin R.L., Cassells J.S., Sell K.W. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1974, 68:258-259.
28. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185:1155-1164.
29. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
30. Epstein J.E., Tewari K., Lyke K.E., Sim B.K., Billingsley P.F., Laurens M.B., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 2011, 334:475-480.
31. Luke T.C., Hoffman S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 2003, 206:3803-3808.
32. Seder R.A., Chang L.J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
33. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361:468-477.
34. Roestenberg M., Teirlinck A.C., McCall M.B., Teelen K., Makamdop K.N., Wiersma J., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 377:1770-1776.
35. Nganou-Makamdop K., van Gemert G.J., Arens T., Hermsen C.C., Sauerwein R.W. Long term protection after immunization with P. berghei sporozoites correlates with sustained IFNgamma responses of hepatic CD8+ memory T cells. PLoS ONE 2012, 7:e36508.
36. Bijker E.M., Teirlinck A.C., Schats R., van Gemert G.J., van de Vegte-Bolmer M., van Lieshout L., et al. Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites. J Infect Dis 2014, 210:1605-1615.
37. Hoffman S.L., Billingsley P., James E., Richman A., Loyevsky M., Li T., et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccines 2010, 6:97-106.
38. Roestenberg M., Bijker E.M., Sim B.K., Billingsley P.F., James E.R., Bastiaens G.J., et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2013, 88:5-13.
39. Sheehy S.H., Spencer A.J., Douglas A.D., Sim B.K., Longley R.J., Edwards N.J., et al. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLOS ONE 2013, 8:e65960.
40. Shekalaghe S., Rutaihwa M., Billingsley P.F., Chemba M., Daubenberger C.A., James E.R., et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2014, 91:471-480.
41. Hodgson S.H., Juma E.A., Salim A., Magiri C., Kimani D., Njenga D., et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol 2014, 2014.
42. Mordmüller B., Supan C., Sim K.L., Gómez-Pérez G.P., Ospina Salazar C.L., Held J., et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 2015, 14:117.
43. Bastiaens GJ, van Meer MP, Scholzen A, Obiero JM, Vatanshenassan M, van Grinsven T, et al. Safety, immunogenicity and protective efficacy after intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial, unpublished results.
44. Garcia C.R., Manzi F., Tediosi F., Hoffman S.L., James E.R. Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. Vaccine 2013, 31:380-386.
45. Bijker E.M., Bastiaens G.J., Teirlinck A.C., van Gemert G.J., Graumans W., van de Vegte-Bolmer M., et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA 2013, 110:7862-7867.
46. Gómez-Pérez G.P., Legarda A., Muñoz J., Sim B.K.L., Ballester M.R., Dobaño C., et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates. Malar J 2015, 14:306.
47. Aly A.S., Vaughan A.M., Kappe S.H. Malaria parasite development in the mosquito and infection of the mammalian host. Annu Rev Microbiol 2009, 63:195-221.
48. van Buskirk K.M., O'Neill M.T., De La Vega P., Maier A.G., Krzych U., Williams J., et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci USA 2009, 106:13004-13009.
49. Spring M., Murphy J., Nielsen R., Dowler M., Bennett J.W., Zarling S., et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 2013, 31:4975-4983.
50. Annoura T., Ploemen I.H., van Schaijk B.C., Sajid M., Vos M.W., van Gemert G.J., et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 2012, 30:2662-2670.
51. Mikolajczak S.A., Lakshmanan V., Fishbaugher M., Camargo N., Harupa A., Kaushansky A., et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther 2014, 22:1707-1715.
52. Annoura T., van Schaijk B.C., Ploemen I.H., Sajid M., Lin J.W., Vos M.W., et al. Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development. FASEB J 2014, 28:2158-2170.
53. van Schaijk B.C., Ploemen I.H., Annoura T., Vos M.W., Lander F., van Gemert G.J., et al. A genetically attenuated malaria vaccine candidate based on gene-deficient sporozoites. Elife 2014, 3.
54. Sedegah M., Hedstrom R., Hobart P., Hoffman S.L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994, 91:9866-9870.
55. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476-480.
56. Richie T.L., Charoenvit Y., Wang R., Epstein J.E., Hedstrom R.C., Kumar S., et al. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccines Immunother 2012, 8:1564-1584.
57. Krause A., Joh J.H., Hackett N.R., Roelvink P.W., Bruder J.T., Wickham T.J., et al. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 2006, 80:5523-5530.
58. Ewer K.J., O'Hara G.A., Duncan C.J., Collins K.A., Sheehy S.H., Reyes-Sandoval A., et al. Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013, 4:2836.
59. Tamminga C., Sedegah M., Maiolatesi S., Fedders C., Reyes S., Reyes A., et al. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum Vaccine Immunother 2013, 9:2165-2177.
60. Li S., Rodrigues M., Rodriguez D., Rodriguez J.R., Esteban M., Palese P., et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 1993, 90:5214-5218.
61. Plebanski M., Gilbert S.C., Schneider J., Hannan C.M., Layton G., Blanchard T., et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. J Immunol 1998, 28:4345-4355.
62. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Hobart P., Tine J.A., et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998, 95:7648-7653.
63. Reyes-Sandoval A., Rollier C.S., Milicic A., Bauza K., Cottingham M.G., Tang C.K., et al. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol Ther 2012, 20:1633-1647.
64. Rogers W.O., Weiss W.R., Kumar A., Aguiar J.C., Tine J.A., Gwadz R., et al. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect Immun 2002, 70:4329-4335.
65. Jiang G., Shi M., Conteh S., Richie N., Banania G., Geneshan H., et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS ONE 2009, 4:e6559.
66. Epstein J.E., Charoenvit Y., Kester K.E., Wang R., Newcomer R., Fitzpatrick S., et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 2004, 22:1592-1603.
67. Wang R., Epstein J., Charoenvit Y., Baraceros F.M., Rahardjo N., Gay T., et al. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J Immunol 2004, 172:5561-5569.
68. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003, 9:729-735.
69. Sedegah M., Hollingdale M.R., Farooq F., Ganeshan H., Belmonte M., Kim Y., et al. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes. PLOS ONE 2014, 9:e106241.
70. Chuang I., Sedegah M., Cicatelli S., Spring M., Polhemus M., Tamminga C., et al. DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLOS ONE 2013, 8:e55571.
71. O'Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205:772-781.
72. Hodgson S.H., Ewer K.J., Bliss C.M., Edwards N.J., Rampling T., Anagnostou N.A., et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis 2014, 211:1076-1086.
73. Sheehy S.H., Duncan C.J., Elias S.C., Choudhary P., Biswas S., Halstead F.D., et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2012, 20:2355-2368.
74. Pham N.L., Pewe L.L., Fleenor C.J., Langlois R.A., Legge K.L., Badovinac V.P., et al. Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly. Proc Natl Acad Sci USA 2010, 107:12198-12203.
75. Schmidt N.W., Butler N.S., Harty J.T.C.D8 T cell immunity to Plasmodium permits generation of protective antibodies after repeated sporozoite challenge. Vaccine 2009, 27:6103-6106.
76. Neuenhahn M., Kerksiek K.M., Nauerth M., Suhre M.H., Schiemann M., Gebhardt F.E., et al. CD8alpha+ dendritic cells are required for efficient entry of Listeria monocytogenes into the spleen. Immunity 2006, 25:619-630.
77. Le D.T., Brockstedt D.G., Nir-Paz R., Hampl J., Mathur S., Nemunaitis J., et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012, 18:858-868.
78. Wood L.M., Paterson Y. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol 2014, 4:51.
79. Angov E., Hillier C.J., Kincaid R.L., Lyon J.A. Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS ONE 2008, 3:e2189.
80. Narum D.L., Kumar S., Rogers W.O., Fuhrmann S.R., Liang H., Oakley M., et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun 2001, 69:7250-7253.
81. Terheggen U., Drew D.R., Hodder A.N., Cross N.J., Mugyenyi C.K., Barry A.E., et al. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines. BMC Med 2014, 12:183.
82. Dobano C., Widera G., Rabussay D., Doolan D.L. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine 2007, 25:6635-6645.
83. Bruder J.T., Semenova E., Chen P., Limbach K., Patterson N.B., Stefaniak M.E., et al. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS ONE 2012, 7:e33920.
84. Hutchings C.L., Birkett A.J., Moore A.C., Hill A.V. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect Immun 2007, 75:5819-5826.
85. Draper S.J., Biswas S., Spencer A.J., Remarque E.J., Capone S., Naddeo M., et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 2010, 185:7583-7595.
86. Biswas S., Choudhary P., Elias S.C., Miura K., Milne K.H., de Cassan S.C., et al. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLOS ONE 2014, 9:e107903.
87. Hodgson S.H., Choudhary P., Elias S.C., Milne K.H., Rampling T.W., Biswas S., et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. Mol Ther 2014, 22:2142-2154.
88. Reddy K.S., Pandey A.K., Singh H., Sahar T., Emmanuel A., Chitnis C.E., et al. Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. Infect Immun 2014, 82:152-164.
89. Duffy P.E., Sahu T., Akue A., Milman N., Anderson C. Pre-erythrocytic malaria vaccines: identifying the targets. Expert Rev Vaccines 2012, 11:1261-1280.
90. Gwadz R.W., Carter R., Green I. Gamete vaccines and transmission-blocking immunity in malaria. Bull World Health Organ 1979, 57(Suppl. 1):175-180.
91. Gwadz R.W. Successful immunization against the sexual stages of Plasmodium gallinaceum. Science 1976, 193:1150-1151.
92. Carter R., Chen D.H. Malaria transmission blocked by immunisation with gametes of the malaria parasite. Nature 1976, 263:57-60.
93. Dinglasan R.R., Kalume D.E., Kanzok S.M., Ghosh A.K., Muratova O., Pandey A., et al. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc Natl Acad Sci USA 2007, 104:13461-13466.
94. Carter R., Miller L.H., Rener J., Kaushal D.C., Kumar N., Graves P.M., et al. Target antigens of malaria transmission blocking immunity. Philos Trans R Soc Lond Ser B: Biol Sci 1984, 307:201-213.
95. Rener J., Carter R., Rosenberg Y., Miller L.H. Anti-gamete monoclonal antibodies synergistically block transmission of malaria by preventing fertilization in the mosquito. Proc Natl Acad Sci USA 1980, 77:6797-6799.
96. Kaushal D.C., Carter R., Rener J., Grotendorst C.A., Miller L.H., Howard R.J. Monoclonal antibodies against surface determinants on gametes of Plasmodium gallinaceum block transmission of malaria parasites to mosquitoes. J Immunol 1983, 131:2557-2562.
97. Ockenhouse C.F., Sun P.F., Lanar D.E., Wellde B.T., Hall B.T., Kester K., et al. Phase I/IIa safety, immunogenicity and efficacy of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998, 177:1664-1673.
98. Gozar M.M., Price V.L., Kaslow D.C. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect Immun 1998, 66:59-64.
99. Gozar M.M., Muratova O., Keister D.B., Kensil C.R., Price V.L., Kaslow D.C. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. Exp Parasitol 2001, 97:61-69.
100. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005, 23:3131-3138.
101. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008, 3:e2636.
102. Wu Y., Przysiecki C., Flanagan E., Bello-Irizarry S.N., Ionescu R., Muratova O., et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci USA 2006, 103:18243-18248.
103. Qian F., Wu Y., Muratova O., Zhou H., Dobrescu G., Duggan P., et al. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine 2007, 25:3923-3933.
104. Shimp R.L., Rowe C., Reiter K., Chen B., Nguyen V., Aebig J., et al. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Vaccine 2013, 31:2954-2962.
105. Jones R.M., Chichester J.A., Mett V., Jaje J., Tottey S., Manceva S., et al. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PLOS ONE 2013, 8:e79538.
106. WHO. Malaria vaccine rainbow tables. Available from: [accessed 04.01.15]. http://www.who.int/vaccine_research/links/Rainbow/en/index.html.
107. Penny M.A., Maire N., Studer A., Schapira A., Smith T.A. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE 2008, 3:e3193.
108. Nunes J.K., Woods C., Carter T., Raphael T., Morin M.J., Diallo D., et al. Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward. Vaccine 2014, 32:5531-5539.
109. Blagborough A.M., Churcher T.S., Upton L.M., Ghani A.C., Gething P.W., Sinden R.E. Transmission-blocking interventions eliminate malaria from laboratory populations. Nat Commun 2013, 4:1812.
110. Blagborough A.M., Yoshida S., Sattabongkot J., Tsuboi T., Sinden R.E. Intranasal and intramuscular immunization with Baculovirus dual expression system-based Ps25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 2010, 28:6014-6020.